139 related articles for article (PubMed ID: 37750641)
21. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
22. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
[TBL] [Abstract][Full Text] [Related]
23. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
[TBL] [Abstract][Full Text] [Related]
24. Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer.
Conley AB; Fournier KF; Sood AK; Frumovitz M
Obstet Gynecol; 2023 May; 141(5):1019-1023. PubMed ID: 37023452
[TBL] [Abstract][Full Text] [Related]
25. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
[TBL] [Abstract][Full Text] [Related]
26. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
27. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
[TBL] [Abstract][Full Text] [Related]
28. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
29. Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients.
Zhang J; Li XB; Ji ZH; Ma R; Bai WP; Li Y
Biomed Res Int; 2021; 2021():5533134. PubMed ID: 34258265
[TBL] [Abstract][Full Text] [Related]
30. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal sarcomatosis-A systematic review and meta-analysis.
Wong LCK; Li Z; Fan Q; Tan JW; Tan QX; Wong JSM; Ong CJ; Chia CS
Eur J Surg Oncol; 2022 Mar; 48(3):640-648. PubMed ID: 34716035
[TBL] [Abstract][Full Text] [Related]
31. Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial.
Antonio CCP; Alida GG; Elena GG; Rocío GS; Jerónimo MG; Luis ARJ; Aníbal ND; Francisco BV; Jesús GRÁ; Pablo RR; José GM
Ann Surg Oncol; 2022 Apr; 29(4):2617-2625. PubMed ID: 34812982
[TBL] [Abstract][Full Text] [Related]
32. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
[TBL] [Abstract][Full Text] [Related]
33. Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis.
Kim SI; Cho J; Lee EJ; Park S; Park SJ; Seol A; Lee N; Yim GW; Lee M; Lim W; Song G; Chang SJ; Kim JW; Kim HS
Medicine (Baltimore); 2019 Dec; 98(50):e18355. PubMed ID: 31852138
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer.
Ayhan A; Akilli H
Int J Gynaecol Obstet; 2021 Feb; 152(2):202-207. PubMed ID: 33020918
[TBL] [Abstract][Full Text] [Related]
35. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
37. Mininvasive Cytoreduction Surgery plus HIPEC for Epithelial Ovarian Cancer: A Systematic Review.
Ronsini C; Pasanisi F; Greco P; Cobellis L; De Franciscis P; Cianci S
Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984422
[No Abstract] [Full Text] [Related]
38. Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent ovarian cancer: When, and for whom?
Ayhan A; Akilli H; Abasiyanik MA; Taskiran C
J Surg Oncol; 2023 Mar; 127(3):457-464. PubMed ID: 36264620
[TBL] [Abstract][Full Text] [Related]
39. Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer: An Umbrella Review of Meta-Analyses.
Souadka A; Essangri H; Majbar MA; Benkabbou A; Boutayeb S; You B; Glehen O; Mohsine R; Bakrin N
Front Oncol; 2022; 12():809773. PubMed ID: 35615149
[TBL] [Abstract][Full Text] [Related]
40. Incisional hernias post cytoreductive surgery/peritonectomy and hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis.
Mac Curtain BM; Qian W; Temperley HC; Simpkin AJ; Ng ZQ
Hernia; 2023 Oct; 27(5):1067-1083. PubMed ID: 37653188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
